

# Around the Corner

# **Rritual Superfoods Inc.**

Healthcare

#### 16 July 2021

Matthew Pepler | Associate | Canaccord Genuity Corp. (Canada) | mpepler@cgf.com | 1.416.546.3728

Canaccord Genuity is providing this report solely for the purpose of investor information and is not providing a recommendation, rating, or price target with respect to the securities or the subject companies discussed in this report.

### **Overview**

Rritual Superfoods Inc. (RSF-CSE) is an award-winning functional mushroom and adaptogenic superfood company that underwent an initial public offering (IPO) in December 2020. More than a functional food company, Rritual is a Superfood Platform. The company's platform specializes in the formulation and distribution of plant-based products that offer consumers the health benefits of adaptogens (herbal pharmaceuticals), superfoods, and functional mushroom-enriched food and beverages. The Rritual platform aims to continue securing premium retail shelf space while constantly innovating to provide consumers with an advanced pipeline of products. The platform also aims to educate consumers on the benefits of the company's products through informational material available online and in store. The Rritual platform provides a world of like-minded health and wellness experts aiming to provide consumers with an award-winning lineup of superfood products.

#### **Inception of Rritual Superfoods Inc.**

Rritual Superfoods is composed of a group of like-minded executives with an extensive combined history in the health and wellness industry. The company is led by CEO David Kerbel, who brings over 30 years of senior experience in retail, brokerage, and consumer packaged goods (CPG). Before joining Rritual, Mr. Kerbel served as an executive with Crossmark, one of the world's largest CPG brokerages. Through Mr. Kerbel's history with Crossmark, Rritual was able to establish a relationship with the company to help build Rritual's retail presence and brand awareness. Mr. Kerbel also has international experience in the UK with Franklin Farms, where he led sales, operations, and the development of new products.

Mr. Kerbel believes there is an opportunity for Rritual to establish itself as a leading brand in the functional food space, where there is currently no one dominant force. With a board of executives that has over 100+ years of combined experience in the health and wellness industry, Rritual believes it is well positioned to establish itself at the forefront of the space with industry-leading products.

By the end of this year, Mr. Kerbel expects that, with the help of partnerships, the company's products will be available in over 2,400 stores, noting that Rritual has already exceeded 10,000 points of distribution, more than any other player in the space.

# Management aims to become a dominant brand in the functional food market

While there are several players in the space, Rritual Superfoods believes it is well positioned to become a dominant force in the \$275 billion functional food market. With product and innovation that meets consumer demand, along with Rritual's current partnerships, the company believes it can successfully compete with competitors in the industry such as Larid Superfood and Four Sigmatic. The global functional mushroom market is valued at \$50 billion, with recent data showing there has been up to an 800% increase in consumer demand for key mushroom varieties today (Grandview Research, Figure 2)

As the industry grows, the company believes there is an opportunity for a premium brand to establish itself while there remains a white space in the market. As Rritual builds its market awareness and continues brand development and innovation, the company is aware that larger wellness players are beginning to take notice and are potentially prepared to make acquisitions.

Key Metrics		Management		Headquarters
Price Market Cap (M) Shares Out (M)	C\$0.57 C\$34.18 62.06	CFO	David Kerbel Robert Payment Warren Spence Stacie Gillespie	Rritual Superfoods Inc. 151 West Hastings Street Vancouver, BC, V6B 1H4 +1.778.400.1242

Canaccord Genuity is the global capital markets group of Canaccord Genuity Group Inc. (CF : TSX)

The recommendations and opinions expressed in this research report accurately reflect the research analyst's personal, independent and objective views about any and all the companies and securities that are the subject of this report discussed herein.

# For important information, please see the Important Disclosures beginning on page 12 of this document.



# Company overview

Founded in 2019, Rritual Superfoods is a natural wellness company that focuses on plant-based product innovation using functional mushroom and adaptogenic herbs as the active ingredients. Adaptogens are natural healing blends of medicinal mushrooms, super herbs, roots, and fruit powders. First documented in the 1950s, these substances are believed to produce resistance to stress in animals and humans. Since then, further research has suggested that adaptogens can help strengthen and boost immune systems, as well as optimize mental, cognitive, and digestive health. Rritual's lineup of products includes food, beverages, and powdered elixirs intended to provide beneficial superfood nutrients.

Since the company's inception, Rritual has been focused on developing its online sales platform, building up its supply chain infrastructure, and establishing an experienced consumer goods team, as well as on the research, innovation, and branding of its mushroom adaptogen formulations. The company's initial products, powder elixirs, fall under the \$250+ billion nutraceutical market that is expected to grow at a compound annual growth rate (CAGR) of 7.9% by 2025, according to Grandview Research. Ready to drink (RTD) powdered elixirs fall in the health and wellness beverage industry, which was valued as a \$41 billion global market in 2015 and poised for steady growth. The objective of Rritual Superfoods is to grow the company's product awareness and become a leader in mental fitness through the creation of great-tasting and easy-to-use supplements. Rritual's products can be purchased in North America through various e-commerce outlets and retail sales channels.

#### Figure 1: Investor summary



CSE : RSF

INVESTOR SUMMARY

# Premium Plant-Based Elixirs, Superfood Dominance.

Powerhouse Team of CPG	Retail Commitments	Revenue Projections
Over 100+ years of combined specialty CPG experience with leading brands such as Celsius Beverages, Nude Beverages, Gaia Herbs, MegaFoods, Nutiva, & Danone	Anticipating 2,400 stores & 10,000 points of distribution* •Already exceeded	2021: \$8.4M USD* 2022: \$16.7M USD* 2023: \$25.1M USD*
The Only Premium Brand	Rapidly Emerging Space	Opportunity to Dominate
of adaptogen elixirs validated by recent ECRM buyers choice award	Whole Foods recently named 'functional foods and adaptogens' as #1 top food trend for 2021	the functional mushroom & adaptogen space with clear points of differentiation

Source: Company presentation

CSE : RSF

# Industry overview

The functional food market is expected to grow at a CAGR of 7.9% over 2020-2025 (source: Grandview Research; Figure 2). Functional mushrooms and adaptogens are used for a variety of applications in healthcare and pharmaceutical products, including food, drink, supplements, and beauty supplies. As the demand for functional mushroom ingredients continues to grow, the addressable market is expanding accordingly. The company cites various studies on the benefits of functional mushrooms that have confirmed the ability of organic mushrooms and adaptogenic herbs to help support a healthy response to stress and optimize mental, cognitive, digestive, and immune health.

The global functional mushroom market is represented by product type, application, and geography. By product, there are six dominant types: Reishi, Cordyceps, Lion's Mane, Turkey Tail, Shiitake, and Chaga. By application, there are food and beverage, dietary supplements, personal care, and pharmaceutical products. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the rest of the world.

The functional food market has seen a rise in popularity over the last two decades. People are far more aware of diseases thought to be related to the consumption of certain food and beverage products than they have been in the past. As a result, consumers are shifting toward functional foods and beverages that promote benefits beyond basic nutrition. The recent buzz behind the superfood market has led to a higher demand for functional mushrooms, which is shown by the consistent growth and awareness of the space in the last few years.

### Figure 2: Industry overview

Rritual

# A State of Rapid Growth, But No Brand Leader...Yet.

\$50 Billion

Global functional mushroom market projected to exceed \$50B by 2025<sup>1</sup>

CAGR 7.9%

Global functional food market to reach \$275B by 2025 with a CAGR of 7.9%<sup>1</sup> + 800%

Recent data shows **up to 800% demand increase** for key mushroom varieties<sup>2</sup>

dominant

Early stage of industry maturity means no dominant brand in place

# premium

Gaps remain in the market, including complete absence of a premium brand

acquisitions +

Wellness players watching the market and beginning to make acquisitions

1 Grandview Research, Functional Foods Market Size, Share & Trends Analysis, 2019 2 Food Navigator, 2020

Source: Company presentation

# Product overview

Rritual Superfoods has four products in the functional food market. Functional foods and "superfoods" offer a high level of nutritional value due to their density of vitamins, minerals, antioxidants, and other compounds thought to boost immunity and improve brain function. The company offers consumers three functional mushroom adaptogen formulations: Chaga, Reishi and Lion's Mane, all USDA-certified organic and caffeine-free.

**Chaga Immune**: Immune Booster – Chaga has been widely used in Eastern and Western herbalism to support healthy immune function and well-being. High in bioactive polysaccharides, Rritual's chaga blend combines Chaga mushroom with Eluithero Root for optimal immune system benefits.

**Lion's Mane Focus**: Brain Booster –A Mushroom long believed in Eastern Herbalism to support brain health, Lion's Mane has recently been recognized as nootropic, which means it help activates and clear the mind for optimal cognitive performance. This blend of Lion's Mane mushroom and Rhodiola root is intended to support cognitive function and brain health, while also maintaining the body's ability to manage stress.

**Reishi Relax (2020 Buyers Choice Award Winner):** Stress support – known as "the mushroom of immortality" in traditional Eastern herbalism, Reishi is popular around the world today for its ability to help the body adapt to stress. Rich in triterpenes, polysaccharides, fatty acids, and amino acids. Rritual's Reishi blend includes ashwagandha root to help support body and mind, and combat anxiety. Long-term use may also help maintain quality of sleep for restless minds.

#### Figure 3: Product overview



Source: Company presentation

#### Figure 4: Product overview



Source: Company presentation

Source: Company presentation

Figure 5: Product overview


The three formulations are offered in two packaging options: Container Mixes and Elixir Stix. The Container Mix includes the same formulation as the Elixir Stix but comes in a 180-gram container, providing an efficient way to consume Rritual's product. The Elixir Stix are individually packed in 3-gram packets, 14 packets per box for a quick mixing solution added to any beverage. The boxes are sold individually through the company's e-commerce channels as well as to wholesalers in a larger package of 12 boxes per order. Rritual believes its proprietary Immune-Synergy Six Mushroom Blend is the only functional health product on the market that contains a daily prebiotic blend that nourishes a healthy gut microbiome and facilitates balanced digestive function.

anaccord

enuitv



#### Figure 6: Rritual's award-winning product



Source: Company presentation

# Product pipeline

### **Expanding product SKUs**

Rritual is continuing to develop new products aimed at meeting and exceeding consumers' needs. The company will be introducing two new superfood products in the fall of 2021 that aim to provide consumers with "skin-deep beauty".

The new latte powder mixes aim to boost energy and cognitive performance. The new superfood latte blend will offer a Blushing Rose Chai flavor that boasts a hot mushroom powder mix formulated with tremella or snow mushroom extract, reishi, and an array of botanicals and berries that the company claims will help promote healthy and hydrated skin, nails and hair, all while being more sustainable and animal-friendly.

Tremella fuciformais is an antioxidant-rich mushroom the company markets to help maintain healthy levels of collagen, helping keep skin hydrated, toned and youthful.



Rritua

### Figure 7: What's next for Rritual

#### CSE : RSF

Investor Information

# What's Next for Rritual

Innovation and quality are at the core of everything we do. We continue to develop our offering to meet and exceed our customer's needs.

Product Innovation Pipeline Preview:



#### Vegan Chai Rose Latte Collagen Booster

Collagen-Booster Rose Chai Latte Powder Made with tremella, reishi, aloe vera and other beautifying superfoods in a skin-hydrating & vegan oream base.



Mood & Energy Ube Matcha Latte Powder

Made with Cordyceps, lion's mane, matcha & purple/blue hue super foods (ube purple sweet pea powder, purple pea flower, blue spirulina) broad-spectrum of prebiotio superfoods of purple sweet potato powder, lucuma, and inulin which combined support a healthy microbiome so you can trust your gut again.



Superfood Vegan Creamer Made with vegan cream base and proprietary immune synergy blend with key adaptogenic botanicals.

Source: Company presentation

# Licensing, operations, and distribution

### US and Canada: Licensing and operations

#### Canada

In Canada, mushroom products can be placed in two categories: (1) food and beverage products and (2) natural health products (NHPs). Rritual's formulations fall under the NHP (powdered elixirs) category, while it continues working to develop innovative products for the food and beverage market. For now, in the company's operating category, any facility in which NHPs are manufactured, imported, labelled and distributed or stored must have a site license from Health Canada. All NHPs are required to have a natural product number (NPN), which is a license issued by Health Canada and must appear on each product's label before it can be sold in Canada.

### **United States**

In the United States, Rritual Superfoods markets its mushroom products as dietary supplements. The company's operations, including the formulation, manufacturing, importation, labelling and distribution, and sale of its products, are all activities that are subject to regulations from the FDA, the FTC, and other governmental agencies.

As Rritual Superfoods continues to grow the brand, the company continues to follow its 3-stage global distribution plan (Figure 8).



### Figure 8: Global distribution



Source: Company presentation

# Partnerships

# Crossmark

Rritual has announced a partnership agreement with Crossmark, a leading national sales and marketing agency in North America with over 100 years of experience, extensive relationships and a team of 25,000+ experienced employees. Crossmark has a portfolio of clients including the likes of Hershey's, Kraft Heinz, Johnson & Johnson, and more. Rritual hopes Crossmark will help it deliver on the 3-year plan to exceed 40,000 points of distribution in the USA in 1.5 years. Rritual expects this collaboration will increase the company's retail store presence and brand awareness.



#### Figure 9: Crossmark's brands



Amazon

Rritual has announced that the company is now partnered with Orca Pacific, an agency of Amazon. This partnership allows Orca to begin the creation, development and optimization of Rritual's Amazon store. Orca will also lead the company's digital marketing strategy. Rritual believes its corporate mission to supply product within "an arm's length" for customers will be significantly increased by this partnership.

#### **The Good Trends**

Rritual has listed its products with The Good Trends, a leader in the B2B wholesale marketplace, providing neighborhood and independently owned retailers access to brands like Rritual Superfoods through its technology platform.

# CVS

Rritual has announced that the company's product will launch in CVS stores across the USA. In 2020, CVS opened 650 HealthHub locations and plans to have 1,500 locations opened by the end of 2021. CVS HealthHub locations offer online streams of wellness and nutrition content. The store will carry Rritual's full individual product line including Chaga Immune, Lion's Mane and Reishi Relax. Rritual will work to develop an in-store education program for CVS-trained professionals to best serve consumers. Rritual will educate these professionals about the company's USDA-Certified organic, caffeine-free options that can be mixed with other beverages or enjoyed on their own.

# **Rite Aid**

Rritual Superfood's also has established a partnership with Rite Aid to accelerate and improve the outreach of in-store sales to consumers. The agreement puts Rritual's three current SKU's – Chaga, Lion's Mane, and Reishi – as well as a mixed pack, in 1,000 stores nationwide.



#### Figure 10: Powerhouse partnerships



Source: Company Presentation

# Competitors

#### Laird

Laird Superfood is engaged in manufacturing and marketing highly differentiated plant-based and functional foods. The product portfolio includes organic mushrooms, coconut water, coconut sugar, mushroom coffee, and other related products. The company was founded in 2015 and has 150 employees. Last year, the company's fourth-quarter net sales increased 75% year over year, to 7.3 million. Online sales contributed 61% of net sales with sales growing 170% year over year and subscribers growing by 184%. The company has 20,000 points of distribution to date, and wholesale sales contributed 37% of net sales, increasing by 45% year over year as retail door expansion reached approx. 7,100 locations.


#### **Four Sigmatic**

Four Sigmatic is a Finnish-American company that combines mushroom products with traditional Finnish coffee replacements. The company was founded in 2012 in Finland, starting with medicinal mushroom products that include drinks, extracts and elixirs. After a relaunch in 2015 to enter the health product space, Four Sigmatic relocated to Los Angeles where it is now headquartered. The company aims to source the world's best mushroom ingredients to combine coffee replacements and health beneficial drinks. The formulas vary from morning routine coffee and latte blends to an evening routine beverage of mushroom cacao with Reishi, intended to help the consumer relax in the evening for a better start in the morning. The company also offers a plant-based protein which includes superfoods,



to make immune-supporting smoothies, protein shakes, and pancakes. With adaptogens being the center of attention, Four Sigmatic products are intended to offer health benefits across the entire product line.

#### Figure 11: Rritual's Competitors



Source: Company Presentation

# Management team

# David Kerbel - Chief Executive Officer and Director

Mr. Kerbel has over 30 years of senior level executive experience in the retail, brokerage and consumer products industries. He served as a senior executive with Crossmark, one of the world's largest CPG brokerages, running the Northeast division, and has international sales experience with the company's UK efforts at Franklin Farms where he led sales, operations and new product development. Mr. Kerbel will be responsible for the day-to-day affairs of the company. Mr. Kerbel holds a Bachelor of Science in business from Suffolk University.

#### Warren Spence - Director

Mr. Spence has over 25 years in the Canadian food and beverage industry, beginning with Olivieri Pasta (Canada Bread). Following this, he spent six years with Yves Veggie Cuisine and 10 years with Red Bull Canada. He has spent the past four years helping start-up companies implement supply chain and operations systems. Mr. Spence was appointed Head of Supply Chain for Nude Beverages just over a year ago. Mr. Spence's responsibilities will be providing strategic oversight of the company's procurement and supply chain as well as mentoring logistics personnel. Mr. Spence attended Simon Fraser University from 1986 to 1988.

# Stacey Gillespie - CCO & Chief Innovation officer

Ms. Gillespie brings 25+ years of experience in brand and product strategy for wellness companies such as Megafood, Aura Caica and Gaia Herbs. At Gaia Herbs, she led the company's brand strategy and worked on the product pipeline and product strategy. Ms. Gillespie was the centre of consumer and category expertise, leading all consumer, industry and market research initiatives. She holds a BSc in Human Nutrition from The University of British Columbia.

### David Lubotta - Director

David Lubotta brings over 20 years of entrepreneurial, corporate finance, innovation, and leadership experience to his role as a director of Rritual. His experience and significant interests in wellness and innovation have led him to be an advisor to Delos Living LLC, and the founding partner Delos Ventures and Delos Canada. Mr. Lubotta is also an advisor to PYM, a consumer product company focused on mental wellness, in addition to being the Managing Partner of DML Ventures. He is a partner at Merida Capital Partners, a leading Cannabis private equity group, headquartered in New York City, with 46 companies in its portfolio. Mr. Lubotta's responsibilities will be to provide strategic oversight and direction for the company. He holds an MBA from Kellogg, School of Management (Northwestern University).

# Scott Eldridge - Director

Scott Eldridge is experienced in the financial industry, focused on the resource sector. He is a co-founder, President and CEO of Euroscandic International Group Inc., a private company offering accounting and investment banking services to natural resource companies. During his time in the industry, Mr. Eldridge has been responsible for raising in excess of \$500 million in combined equity and debt financing for mining projects varying from exploration to construction financing around the globe. Mr. Eldridge's responsibilities will be to provide strategic oversight and direction for the company. He holds a B.B.A. from Capilano University and an M.B.A. from Central European University.

#### Sarton Molnar-Fenton - VP Sales, USA

Ms. Molnar-Fenton started her career working at Vitamin Water and has since worked for large companies such as Danone, Nestle, and FIJI Water. At Nestle as the National Sales Manager for Tibe Hummus, Ms. Molnar-Fenton managed a \$20 million territory and successfully drove accounts such as Shaws, Trader Joes, C&S and more to double-digit growth. Ms. Molnar-Fenton brings extensive sales experience in the food and beverage industry along with leadership experience. She holds a BSBA in Business from Northeastern University.

#### Jessica Malach - VP Corporate Development

With 15+ years leading growth strategies in the natural consumer packaged goods (CPG) sector in the US and Canada, Ms. Malach brings experience from senior roles with Vega, Pinto, and Social Nature. Jessica is a keynote speaker on consumer trends with CHFA and has been featured in publications such as Natural Foods Merchandiser, Whole Foods Magazine, and Food in Canada, to name a few. She holds a BBA in Marketing from Simon Fraser University.

#### Peter Palarchio - Director of Marketing

Mr. Palarchio is a highly regarded brand specialist with over 10 years of marketing management experience. His career has spanned two respected agencies, television, broadcast and global hospitality companies. He is a Partner at Nav43 with experience working at firms such as Navigate Group and Icon Legacy Hospitality. Mr. Palarchio holds an Economics degree from the University of Waterloo.



# Appendix: Important Disclosures

# **Analyst Certification**

Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst's knowledge, she/he is not in receipt of material non-public information about the issuer.

Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

# Sector Coverage

Individuals identified as "Sector Coverage" cover a subject company's industry in the identified jurisdiction, but are not authoring analysts of the report.

# **Investment Recommendation**

Date and time of first dissemination: July 16, 2021, 09:59 ET Date and time of production: July 16, 2021, 09:59 ET

# **Distribution of Ratings:**

# Global Stock Ratings (as of 07/16/21)

Rating	Coverag	IB Clients	
	#	%	%
Buy	642	66.12%	42.99%
Hold	157	16.17%	21.66%
Sell	11	1.13%	36.36%
Speculative Buy	152	15.65%	67.11%
	971*	100.0%	

\*Total includes stocks that are Under Review

# **Canaccord Genuity Ratings System**

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.

HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.

**SELL**: The stock is expected to generate negative risk-adjusted returns during the next 12 months.

**NOT RATED:** Canaccord Genuity does not provide research coverage of the relevant issuer.

"Risk-adjusted return" refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.

# **Risk Qualifier**

**SPECULATIVE**: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

# 12-Month Recommendation History (as of date same as the Global Stock Ratings table)

A list of all the recommendations on any issuer under coverage that was disseminated during the preceding 12-month period may be obtained at the following website (provided as a hyperlink if this report is being read electronically) <a href="http://disclosures-mar.canaccordgenuity.com/EN/Pages/default.aspx">http://disclosures-mar.canaccordgenuity.com/EN/Pages/default.aspx</a>

# Required Company-Specific Disclosures (as of date of this publication)

# **Past performance**

In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance.



# **Online Disclosures**

Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity's policies and procedures regarding the dissemination of research by following the steps outlined above.

# **General Disclaimers**

See "Required Company-Specific Disclosures" above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, "Compendium Reports." "Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80%-owned by Canaccord Genuity Group Inc.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne.

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research.

Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity's policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity's policy is available upon request.

The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity's judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity's affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

# **Research Distribution Policy**

Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity's customers who are entitled to receive the firm's research. In addition research may be distributed by the firm's sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity's customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent.

For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

# Short-Term Trade Ideas

Research Analysts may, from time to time, discuss "short-term trade ideas" in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term 'Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or "Speculative Buy' could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity's research.

# For Canadian Residents:

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

# For United States Persons:

Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

# For United Kingdom and European Residents:

This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

# For Jersey, Guernsey and Isle of Man Residents:

This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

# For Australian Residents:

This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052.

# For Hong Kong Residents:

This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of



persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

# Additional information is available on request.

Copyright © Canaccord Genuity Corp. 2021 - Member IIROC/Canadian Investor Protection Fund

Copyright © Canaccord Genuity Limited. 2021 - Member LSE, authorized and regulated by the Financial Conduct Authority.

Copyright © Canaccord Genuity LLC 2021 - Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited. 2021 – Participant of ASX Group, Chi-x Australia and of the NSX. Authorized and regulated by ASIC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.